^
Association details:
| Biomarker: | Chr t(14;21)(q22;q22) |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | flotetuzumab (MGD006) (CD3 agonist, CD123 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in a Primary Refractory t-AML Patient
Published date:
11/29/2018
Excerpt:
The patient was subsequently treated on a Phase 1 trial of flotetuzumab (MGD006/S80880) (FLZ)....prior to FLZ, BM blasts demonstrated clonal evolution with a complex karyotype (92,XXXX, t(14;21)(q22;q22))....patient received a total of 3 cycles (28 days/cycle) of FLZ. After one FLZ cycle, the patient achieved a (complete response) CR....after 2 additional cycles of FLZ consolidation, the CR was maintained...
DOI:
10.1182/blood-2018-99-118522
Trial ID:
